Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 156, Issue 8, 2011, Pages 949-959

  Ryu, Seunghyong ^a   Oh, Sohee ^b   Cho, Eun Young ^c   Nam, Hee Jung ^a   Yoo, Jae Hyun ^a   Park, Taesung ^b   Joo, Yeon Ho ^d   Kwon, Jun Soo ^e   Hong, Kyung Sue ^a,c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Samsung Medical Center   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Seoul National University Hospital   (South Korea)

Author keywords

Antipsychotics; EAAC1; Gene gene interaction; Pharmacogenetics; SAPAP3

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; EXCITATORY AMINO ACID TRANSPORTER 3; GENOMIC DNA; PROTEIN; SAD90 PSD95 ASSOCIATED PROTEIN 3; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID TRANSPORT SYSTEM X-AG; ANTIPSYCHOTIC AGENTS; EXCITATORY AMINO ACID AGENTS; EXCITATORY AMINO ACID TRANSPORTER 3; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; NERVE TISSUE PROTEINS; OBSESSIVE-COMPULSIVE DISORDER; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 80054857557     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31242     Document Type: Article

References (62)

1. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Automat Control 19: 716-723.
2. Alevizos B, Papageorgiou C, Christodoulou GN. 2004. Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol 7: 375-377.
3. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. 2006. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 63: 769-776.
4. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. 1997. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283: 226-234.
5. Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR. 1992. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 53: 439-442.
6. Bakshi VP, Geyer MA. 1995. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology (Berl) 122: 198-201.
7. Bakshi VP, Swerdlow NR, Geyer MA. 1994. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271: 787-794.
8. Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI. 1995. Glutamate agonist activity: Implications for antipsychotic drug action and schizophrenia. Neuroreport 6: 2500-2504.
9. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
10. Bienvenu OJ, Wang Y, Shugart YY, Welch JM, Grados MA, Fyer AJ, Rauch SL, McCracken JT, Rasmussen SA, Murphy DL, Cullen B, Valle D, Hoehn-Saric R, Greenberg BD, Pinto A, Knowles JA, Piacentini J, Pauls DL, Liang KY, Willour VL, Riddle M, Samuels JF, Feng G, Nestadt G. 2009. Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study. Am J Med Genet Part B 150B: 710-720.
11. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. 2005. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30: 1735-1740.
12. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW. 1995. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 120: 67-74.
13. Crane J, Fagerness J, Osiecki L, Gunnell B, Stewart SE, Pauls DL, Scharf JM. 2011. Family-based genetic association study of DLGAP3 in Tourette Syndrome. Am J Med Genet Part B 156B: 108-114.
14. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. 2005. Efficiency and power in genetic association studies. Nat Genet 37: 1217-1223.
15. De Haan L, Linszen DH, Gorsira R. 1999. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 60: 364-365.
16. Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M, Himle JA, Leventhal BL, Cook EH Jr, Hanna GL. 2006. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 63: 778-785.
17. Diler RS, Yolga A, Avci A, Scahill L. 2003. Risperidone-induced obsessive-compulsive symptoms in two children. J Child Adolesc Psychopharmacol 13(Suppl 1): S89-S92.
18. Ertugrul A, Anil Yagcioglu AE, Eni N, Yazici KM. 2005. Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry Clin Neurosci 59: 219-222.
19. Ge Y, Dudoit S, Speed TP. 2003. Resampling-based multiple testing for microarray data analysis (with discussion). Test 12: 1-17.
20. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. 1989. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46: 1012-1016.
21. Hahn OS, Ahn JH, Song SH, Cho MJ, Kim JK, Bae JN, Cho SJ, Jeong BS, Suh DW, Hahm BJ, Lee DW, Park JK, Hong JP. 2000. Development of Korean Version of Structured Clinical Interview Schedule for DSM-IV Axis I Disorder: Interrater reliability. J Korean Neuropsychiatr Assoc 39: 362-372.
22. Healy DJ, Meador-Woodruff JH. 1997. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Brain Res Mol Brain Res 47: 331-338.
23. Hoenicka J, Garrido E, Ponce G, Rodriguez-Jimenez R, Martinez I, Rubio G, Jimenez-Arriero MA, Palomo T. 2010. Sexually dimorphic interaction between the DRD1 and COMT genes in schizophrenia. Am J Med Genet Part B 153B: 948-954.
24. Huang YH, Bergles DE. 2004. Glutamate transporters bring competition to the synapse. Curr Opin Neurobiol 14: 346-352.
25. Kim E, Naisbitt S, Hsueh YP, Rao A, Rothschild A, Craig AM, Sheng M. 1997. GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules. J Cell Biol 136: 669-678.
26. Kim SJ, Choi NK, Hong HJ, Hwang YS, Kim YK, Lee HS, Kim CH. 2004. Dimensional analyses of the Yale-Brown obsessive-compulsive scale and Yale-Brown obsessive-compulsive scale checklist. Korean J Psychopharmacol 15: 339-345.
27. Kindler S, Rehbein M, Classen B, Richter D, Bockers TM. 2004. Distinct spatiotemporal expression of SAPAP transcripts in the developing rat brain: A novel dendritically localized mRNA. Brain Res Mol Brain Res 126: 14-21.
28. Kwon JS, Joo YH, Nam HJ, Lim M, Cho EY, Jung MH, Choi JS, Kim B, Kang DH, Oh S, Park T, Hong KS. 2009. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry 66: 1233-1241.
29. Lidsky TI, Yablonsky-Alter E, Zuck L, Banerjee SP. 1993. Anti-glutamatergic effects of clozapine. Neurosci Lett 163: 155-158.
30. Lidsky TI, Yablonsky-Alter E, Zuck LG, Banerjee SP. 1997. Antipsychotic drug effects on glutamatergic activity. Brain Res 764: 46-52.
31. Lim JS, Kim CH. 2008. Assessment of obsessive-compulsive symptoms and obsessive-compulsive disorder. Anxiety Mood 4: 11-18.
32. Lim M, Park DY, Kwon JS, Joo YH, Hong KS. 2007. Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. J Clin Psychopharmacol 27: 712-713.
33. Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. 2003. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 27: 333-346.
34. Meador-Woodruff JH, King RE, Damask SP, Bovenkerk KA. 1996. Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine. Mol Psychiatry 1: 41-53.
35. Nicodemus KK, Law AJ, Radulescu E, Luna A, Kolachana B, Vakkalanka R, Rujescu D, Giegling I, Straub RE, McGee K, Gold B, Dean M, Muglia P, Callicott JH, Tan HY, Weinberger DR. 2010. Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Arch Gen Psychiatry 67: 991-1001.
36. Nicolini H, Arnold P, Nestadt G, Lanzagorta N, Kennedy JL. 2009. Overview of genetics and obsessive-compulsive disorder. Psychiatry Res 170: 7-14.
37. Pauls DL. 2008. The genetics of obsessive compulsive disorder: A review of the evidence. Am J Med Genet Part C 148C: 133-139.
38. Prata DP, Mechelli A, Fu CH, Picchioni M, Toulopoulou T, Bramon E, Walshe M, Murray RM, Collier DA, McGuire P. 2009. Epistasis between the DAT 3' UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia. Proc Natl Acad Sci USA 106: 13600-13605.
39. Riva MA, Tascedda F, Lovati E, Racagni G. 1997. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res 50: 136-142.
40. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. 2000. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39: 1096-1103.
41. Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, Bhandari R, Rose M, Ivey J, Boyd C, Moore GJ. 2004. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 43: 1146-1153.
42. Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, Nash N, Kuncl RW. 1994. Localization of neuronal and glial glutamate transporters. Neuron 13: 713-725.
43. Samuels J, Wang Y, Riddle MA, Greenberg BD, Fyer AJ, McCracken JT, Rauch SL, Murphy DL, Grados MA, Knowles JA, Piacentini J, Cullen B, Bienvenu OJ III, Rasmussen SA, Geller D, Pauls DL, Liang KY, Shugart YY, Nestadt G. 2011. Comprehensive family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder. Am J Med Genet Part B 156B: 472-477.
44. See RE, Lynch AM. 1996. Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats. Eur J Pharmacol 308: 279-282.
45. Shigeri Y, Seal RP, Shimamoto K. 2004. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev 45: 250-265.
46. Shugart YY, Wang Y, Samuels JF, Grados MA, Greenberg BD, Knowles JA, McCracken JT, Rauch SL, Murphy DL, Rasmussen SA, Cullen B, Hoehn-Saric R, Pinto A, Fyer AJ, Piacentini J, Pauls DL, Bienvenu OJ, Riddle MA, Liang KY, Nestadt G. 2009. A family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder in 378 families. Am J Med Genet Part B 150B: 886-892.
47. Stamouli S, Lykouras L. 2006. Quetiapine-induced obsessive-compulsive symptoms: A series of five cases. J Clin Psychopharmacol 26: 396-400.
48. Starck G, Ljungberg M, Nilsson M, Jonsson L, Lundberg S, Ivarsson T, Ribbelin S, Ekholm S, Carlsson A, Forssell-Aronsson E, Carlsson ML. 2008. A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: Relationship between metabolite concentrations and symptom severity. J Neural Transm 115: 1051-1062.
49. Stewart SE, Fagerness JA, Platko J, Smoller JW, Scharf JM, Illmann C, Jenike E, Chabane N, Leboyer M, Delorme R, Jenike MA, Pauls DL. 2007. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet Part B 144B: 1027-1033.
50. Swerdlow NR, Bakshi V, Geyer MA. 1996. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279: 1290-1299.
51. Tadic A, Victor A, Baskaya O, von Cube R, Hoch J, Kouti I, Anicker NJ, Hoppner W, Lieb K, Dahmen N. 2009. Interaction between gene variants of the serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT) in borderline personality disorder. Am J Med Genet Part B 150B: 487-495.
52. Takeuchi M, Hata Y, Hirao K, Toyoda A, Irie M, Takai Y. 1997. SAPAPs. A family of PSD-95/SAP90-associated proteins localized at postsynaptic density. J Biol Chem 272: 11943-11951.
53. Tan HY, Chen Q, Sust S, Buckholtz JW, Meyers JD, Egan MF, Mattay VS, Meyer-Lindenberg A, Weinberger DR, Callicott JH. 2007. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc Natl Acad Sci USA 104: 12536-12541.
54. Wang Y, Adamczyk A, Shugart YY, Samuels JF, Grados MA, Greenberg BD, Knowles JA, McCracken JT, Rauch SL, Murphy DL, Rasmussen SA, Cullen B, Pinto A, Fyer AJ, Piacentini J, Pauls DL, Bienvenu OJ, Riddle M, Liang KY, Valle D, Wang T, Nestadt G. 2010. A screen of SLC1A1 for OCD-related alleles. Am J Med Genet Part B 153B: 675-679.
55. Welch JM, Wang D, Feng G. 2004. Differential mRNA expression and protein localization of the SAP90/PSD-95-associated proteins (SAPAPs) in the nervous system of the mouse. J Comp Neurol 472: 24-39.
56. Welch JM, Lu J, Rodriguiz RM, Trotta NC, Peca J, Ding JD, Feliciano C, Chen M, Adams JP, Luo J, Dudek SM, Weinberg RJ, Calakos N, Wetsel WC, Feng G. 2007. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448: 894-900.
57. Wendland JR, Moya PR, Timpano KR, Anavitarte AP, Kruse MR, Wheaton MG, Ren-Patterson RF, Murphy DL. 2009. A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch Gen Psychiatry 66: 408-416.
58. Westfall PH, Young SS. 1993. Resampling-based multiple testing: Examples and methods for P-value adjustment. New York: John Wiley & Sons.
59. Whiteside SP, Port JD, Deacon BJ, Abramowitz JS. 2006. A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res 146: 137-147.
60. Yamamoto BK, Cooperman MA. 1994. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14: 4159-4166.
61. Yamamoto BK, Pehek EA, Meltzer HY. 1994. Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55(Suppl B): 8-14.
62. Zuchner S, Wendland JR, Ashley-Koch AE, Collins AL, Tran-Viet KN, Quinn K, Timpano KC, Cuccaro ML, Pericak-Vance MA, Steffens DC, Krishnan KR, Feng G, Murphy DL. 2009. Multiple rare SAPAP3 missense variants in trichotillomania and OCD. Mol Psychiatry 14: 6-9.